SB 265610

Drug Profile

SB 265610

Latest Information Update: 04 Feb 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-inflammatories
  • Mechanism of Action Interleukin 8 receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammatory bowel diseases

Most Recent Events

  • 04 Feb 2008 Discontinued - Preclinical for Inflammatory bowel disease in USA (PO)
  • 09 Jun 2004 Data presented at the Digestive Disease Week-2004 (DDW-2004) have been added to the Inflammatory Bowel Disorders pharmacodynamics section
  • 31 Dec 2001 Preclinical development for Inflammatory bowel disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top